Summary

• Page properties (1 modified, 0 added, 0 removed)

Details

Page properties

Content

...	...	@@ -10,55 +10,46 @@
10	10
11	11	32% of its revenue is generated via offshore sales. As well as Alkem Laboratories has consistently been ranked amongst the top ten pharmaceutical companies in India. The company's portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, its dominance in anti-infective segment has remained unchallenged.{{footnote}}https://www.alkemlabs.com/about-us.php{{/footnote}}
12	12
	13	+== Global Presence ==
13	13
14		-Global Presence
	15	+It started with a small step! A step, originating from the idea of increasing Alkem’s global footprint, which eventually became a giant leap for us! For it, United States is the focal point of international operations. In this stride, Alkem Laboratories has cumulatively filed more than 125 ANDAs with the US FDA. Alkem markets and sells products in the United States under its wholly owned subsidiary – Ascend.{{footnote}}https://www.alkemlabs.com/overview.php{{/footnote}}
15	15
16		-
17		-It started with a small step! A step, originating from the idea of increasing Alkem’s global footprint, which eventually became a giant leap for us! For it, United States is the focal point of international operations. In this stride, Alkem Laboratories has cumulatively filed more than 125 ANDAs with the US FDA. Alkem markets and sells products in the United States under its wholly owned subsidiary – Ascend.{{footnote}}http://www.aiaengineering.com{{/footnote}}
18		-
19		-[[https:~~/~~/www.alkemlabs.com/overview.php>>url:https://www.alkemlabs.com/overview.php]]
20		-
21	21	Other international operations include markets like Australia, Europe, Southeast Asia, Latin America, Africa and CIS. The company's products are marketed in about 50 international markets directly through its subsidiaries and indirectly through active engagements with other organizations. Currently, its key markets include Australia, Chile, Philippines and Kazakhstan.
22	22
23		-
24	24	Alkem Laboratories has its own sales and commercial infrastructure in these markets. Alkem Laboratories is constantly looking forward to product in-licensing and out-licensing opportunities in several emerging markets. This helps it leverage its product portfolio, and sales and marketing infrastructure.
25	25
	21	+== Manufacturing Facilities ==
26	26
	23	+Alkem Laboratories is a high quality focused organization. Alkem’s vision and culture of high quality obsession reflects in its operations. The company's manufacturing operations are focused on producing generics, branded generics, over-the-counter (OTC) products, Active Pharmaceutical Ingredients (APIs) and nutraceuticals. These are available in full range of dosage forms, which include, capsules, injectable and liquids. This helps in furnishing quality formulations in India as well as 50 other countries.{{footnote}}https://www.alkemlabs.com/manufacturing-facilities.php{{/footnote}}
27	27
28		-Manufacturing Facilities
29		-
30		-
31		-Alkem Laboratories is a high quality focused organization. Alkem’s vision and culture of high quality obsession reflects in its operations. The company's manufacturing operations are focused on producing generics, branded generics, over-the-counter (OTC) products, Active Pharmaceutical Ingredients (APIs) and nutraceuticals. These are available in full range of dosage forms, which include, capsules, injectable and liquids. This helps in furnishing quality formulations in India as well as 50 other countries.{{footnote}}http://www.aiaengineering.com{{/footnote}}
32		-
33		-[[https:~~/~~/www.alkemlabs.com/manufacturing-facilities.php>>url:https://www.alkemlabs.com/manufacturing-facilities.php]]
34		-
35	35	Alkem Laboratories has state-of-the-art facilities that employ cutting-edge manufacturing techniques for producing best-in-class products. Alkem has an extensive manufacturing footprint which has a total of 21 manufacturing facilities, out of which 19 are in India and 2 are in the United States.
36	36
37		-
38	38	Alkem Laboratories has various manufacturing facilities at Daman, Baddi, Indore and Sikkim. These possess regulatory approvals from agencies such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, ZimbabAlkem Laboratories ,BfArM-Germany & Other Africa, Asian & CIS Countries. They are routinely audited to ensure compliance with Current Good Manufacturing Practices (cGMP).
39	39
40		-
41	41	The company's Production Team has over 3,000 capable individuals, who work in tandem with the Quality Team to deliver top-quality products. The company's management furnishes adequate resources to ensure quality deliverance. All manufacturing units are equipped with Quality Control Units that assure quality at each stage.
42	42
	31	+**Manufacturing Facilities & Capabilities in India**
43	43
44		-Manufacturing Facilities & Capabilities in India
	33	+(% style="width:654px" %)
	34	+|(% style="width:137px" %)**Facilities**|(% style="width:124px" %)**No. of Facilities**|(% style="width:390px" %)**Manufacturing Capabilities**
	35	+|(% style="width:137px" %)Baddi|(% style="width:124px" %)4|(% style="width:390px" %)Formulations - Tablets, Injectables, Dry Syrup
	36	+|(% style="width:137px" %)Sikkim|(% style="width:124px" %)8|(% style="width:390px" %)Formulations - Tablets, Injectables, Dry Syrup
	37	+|(% style="width:137px" %)Daman|(% style="width:124px" %)5|(% style="width:390px" %)Formulations - Capsules, Tablets, Injectables, Dry Syrup
	38	+|(% style="width:137px" %)Mandva|(% style="width:124px" %)1|(% style="width:390px" %)Active Pharmaceutical Ingredients (APIs)
	39	+|(% style="width:137px" %)Ankleshwar|(% style="width:124px" %)1|(% style="width:390px" %)Active Pharmaceutical Ingredients (APIs)
45	45
	41	+**Manufacturing Facilities & Capabilities in the US**
46	46
47		-<table
	43	+(% style="width:657px" %)
	44	+|(% style="width:136px" %)**Facilities**|(% style="width:122px" %)**No. of Facilities**|(% style="width:396px" %)**Manufacturing Capabilities**
	45	+|(% style="width:136px" %)California|(% style="width:122px" %)1|(% style="width:396px" %)Active Pharmaceutical Ingredients (APIs)
	46	+|(% style="width:136px" %)St. Louis (Missouri)|(% style="width:122px" %)1|(% style="width:396px" %)Formulations - Liquids, Nasal Sprays, Semi-solids, Solids
48	48
	48	+= Industry Overview =
49	49
50		-Manufacturing Facilities & Capabilities in the US
	50	+The global pharmaceutical industry is one of the largest and the oldest industries in the world. As per a research report by the IQVIA Institute for Human Data Science, the global pharmaceutical industry is estimated to be US$ 1.25 trillion (at invoice level) in 2019 and is expected to grow at a compounded annual growth rate (CAGR) of 3-6% over 2020-2024 to touch US$ 1.6 trillion in 2024. This growth would primarily be driven by ageing and rising population, improvements in purchasing power, access to quality healthcare by poor and middle-class families worldwide and innovation and advancement in rare and specialty diseases including biologics, nucleic acid therapies and cell therapies. However, adoption of price control policies, tightening of regulations by governments in key markets and loss of exclusivity of large brands would offset some part of this growth.{{footnote}}https://www.alkemlabs.com/pdf/annual-report/Annual_Report_2019-20-2.pdf{{/footnote}}
51	51
52		-<table>
53	53
54		-
55		-Industry Overview
56		-
57		-
58		-The global pharmaceutical industry is one of the largest and the oldest industries in the world. As per a research report by the IQVIA Institute for Human Data Science, the global pharmaceutical industry is estimated to be US$ 1.25 trillion (at invoice level) in 2019 and is expected to grow at a compounded annual growth rate (CAGR) of 3-6% over 2020-2024 to touch US$ 1.6 trillion in 2024. This growth would primarily be driven by ageing and rising population, improvements in purchasing power, access to quality healthcare by poor and middle-class families worldwide and innovation and advancement in rare and specialty diseases including biologics, nucleic acid therapies and cell therapies. However, adoption of price control policies, tightening of regulations by governments in key markets and loss of exclusivity of large brands would offset some part of this growth.{{footnote}}http://www.aiaengineering.com{{/footnote}}
59		-
60		-[[https:~~/~~/www.alkemlabs.com/pdf/annual-report/Annual_Report_2019-20-2.pdf>>url:https://www.alkemlabs.com/pdf/annual-report/Annual_Report_2019-20-2.pdf]]
61		-
62	62	The  major developed markets, comprising the United States (US), top five European markets (Germany, France, Italy, United Kingdom and Spain), Japan, Canada, South Korea and Australia,  will remain the dominant contributor to the global pharmaceutical sales. However, at the same time, the contribution of the  Pharmerging markets (comprising China, Brazil, India, Russia and many others) to global spending is expected to rise over the five-year period to 2024.
63	63
64	64	Branded and Generic Medicines